KRAS and colorectal cancer: In KRAS G12C-mutated colorectal cancer, combining MRTX849 with the anti-EGFR antibody cetuximab achieved an ORR of 34%, a DCR of 85%, and a median PFS of 6.9 months, with favorable outcomes and a tolerable safety profile (55).